bs-0181R-Cy3 [Conjugated Primary Antibody]
Nociceptin receptor Polyclonal Antibody, Cy3 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: Nociceptin receptor

Immunogen Range: 1-47/370


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 18389

Swiss Prot: P35377

Source: KLH conjugated synthetic peptide derived from mouse Nociceptin receptor

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin.

Conjugation: Cy3

Excitation/ Emission: 512,550nm/570,615nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 40


Cross Reactive Species: Human
Mouse
Rat

Predicted Cross Reactive Species: Dog
Cow
Pig
Horse
Guinea Pig

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Xingrao Ke. et al. Adverse Maternal Environment Alters Oprl1 Variant Expression in Mouse Hippocampus. ANAT REC. 2022 AugRead more>>
  • Omar N. Al Yacoub. et al. Recovery from Traumatic Brain Injury Is Nociceptin/Orphanin FQ Peptide Receptor Genotype-, Sex-, and Injury Severity-Dependent. J PHARMACOL EXP THER. 2024 May;389(2):136-149Read more>>
VALIDATION IMAGES